SCHEMBL7367451

SCHEMBL7367451

Cc1ccc(Cc2ccccc2)cc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.68
ESR1 P03372 1/20 0.55
ESR2 Q92731 1/20 0.55
HNF4A P41235 1/20 0.53
MPO P05164 1/20 0.51
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
BCL2 P10415 1/20 0.50
BCL2L1 Q07817 1/20 0.50
CALM1 P0DP23 1/20 0.48
LMNA P02545 1/20 0.46
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL921815 0.89 ESR1 (0.67) IDH1ESR1ESR2CA1CA2
SCHEMBL22864266 0.86 ESR1 (0.57) IDH1ESR1ESR2CA1CA2
SCHEMBL18466197 0.85 KEAP1 (0.59) IDH1ESR1ESR2HNF4ACA1
SCHEMBL9450817 0.84 ESR1 (0.80) IDH1ESR1ESR2HNF4AMPO
SCHEMBL16436964 0.83 CA1 (0.74) IDH1ESR1ESR2CA1CA2
SCHEMBL14384632 0.83 ESR1 (0.65) IDH1ESR1ESR2CA1CA2
SCHEMBL921295 0.82 ESR1 (0.83) IDH1ESR1ESR2CA1CA2
SCHEMBL1584791 0.81 IDH1 (1.00) IDH1HNF4AMPOCA1CA2
SCHEMBL3304087 0.81 CALM1 (0.55) IDH1ESR1ESR2HNF4ACALM1
SCHEMBL15723335 0.80 CA1 (0.68) IDH1ESR1ESR2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117370-A1 REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS OREGON STATE UNIVERSITY (US) 2023-04-20 US disclosed
WO-2021211982-A2 REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS OREGON STATE UNIVERSITY (US) 2021-10-21 WO disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117370-A1 REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS CYP2B6, TYR, CYP2D6 IDH1 1959/4885ESR1 972/4885ESR2 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.